SNG cost ?11 Oct 2022 11:24
Has the company ever said £2k ? I know RM mentioned it in one of the earliest interviews post P2, and (from memory) I think he was making a direct comparison with the Tamiflu cost 8 years earlier (please correct if my memory is faulty) In any case - and whichever drug he cited - it was a comparative comment about something that had subsequently failed to deliver.
That was a long time ago of course, and through the long months of late 20 and the whole of 21 it was a subject for discussion with some posters saying the actual product was not terribly expensive to make. Has anyone ever said it again though ? and has it ever appeared in a company communication ?
Wigster - was the figure of £2k mentioned in the AGM question ?
I do think cost is relevant and I have long thought that SNG001 when finally authorised would be commercialised at a much lower figure.
Remember that RM was talking in the vaccine and treatmentless world of July 21 - when the share price had gone through the roof in a single day and the Health Sec was mentioning Synairgen in the Commons. He was king of the world and he was talking in Big Pharma terms for a drug that might soon (he clearly hoped ) be treating all breathless hospitalised patients. Speaking just as Dexa's results had been announced but long before any other therapeutics has appeared, and when the company clearly thought the next step to authorisation would be speedy and uncomplicated.
In his first Proactive interview he says a couple of interesting things. The first a desire to trail SNG against ventilated patients (which was not possible before the switch from Ineb to Aerogen ) 5 minutes in. and the second a line that suggested he hoped for authorisation without further trialing. Imagine the world if this had come to pass - if the regulators decided to issue a form of EUA to allow the drug to be used immediately for hospitalisations. Instead we know the long road that followed.
Here's that original interview for any nostalgists out there.
4.20 "we've got to finish the analysis of the data, and then we've got to talk to agencies and find out what we need to do to get the package together so that they can give us approvals for the drug "
5.02 " the other thing we want to explore is giving the drug to ventilated patients"
https://www.youtube.com/watch?v=yaAiafidyi0&t=323s
It's clear that the cheap pill idea has a strong hold on both sides of the Atlantic, with Dexa, Molnupiravir and Paxlovid all fitting a model Fauci has been chasing since the pandemic began - but it's also clear that as Gunto's analysis shows - once patients reach ICU the costs are so astronomical that £2k for a drug that reduced time in those beds and saved the worst progression would be a mere atomised droplet in the ocean.
Sign In
Follow the stocks
